Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
J Hematol Oncol. 2020 Nov 9;13(1):150. doi: 10.1186/s13045-020-00980-5.
The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody-drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens.
随着包含蛋白酶体抑制剂 (PI)、免疫调节剂、单克隆抗体 (MoAb) 和干细胞移植的治疗方案的应用，多发性骨髓瘤 (MM) 的治疗效果已经得到了显著改善。然而，复发和难治性 MM（RRMM）仍然是一个重大挑战。新型药物和治疗方案正在积极的临床开发中。这些包括新型 PI 如 ixazomib、marizomib 和 oprozomib；新型 MoAbs 如 isatuximab 和 MOR202；新型表观遗传药物 ricolinostat 和新型细胞因子如 siltuximab。最近，第一个 XPO-1 抑制剂 selinexor 被批准用于 RRMM。BCMA 靶向 BiTE、抗体药物偶联物和 CAR-T 细胞有可能彻底改变 RRMM 的治疗方法。在这篇综述中，我们总结了这些新型药物和治疗方案的最新临床进展。
